within Pharmacolibrary.Drugs.ATC.L;

model L01BC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.4266666666666665,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.0502,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Gemcitabine is a nucleoside analog used as an antineoplastic (anticancer) agent. It is approved and widely used for treatment of various carcinomas, including pancreatic cancer, non-small cell lung cancer, bladder cancer, and breast cancer. It works primarily by inhibiting DNA synthesis, leading to cell death.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (both sexes), typically aged 18-80 years, receiving intravenous infusion of gemcitabine. No major differences were observed based on sex or cancer type.</p><h4>References</h4><ol><li><p>Thompson, BR, et al., &amp; Smith, DE (2020). Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. <i>Biochemical pharmacology</i> 180 114127–None. DOI:<a href=&quot;https://doi.org/10.1016/j.bcp.2020.114127&quot;>10.1016/j.bcp.2020.114127</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32603666/&quot;>https://pubmed.ncbi.nlm.nih.gov/32603666</a></p></li><li><p>Alharbi, AF, et al., &amp; Kirstein, MN (2019). Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. <i>Cancer chemotherapy and pharmacology</i> 83(2) 387–391. DOI:<a href=&quot;https://doi.org/10.1007/s00280-018-3757-7&quot;>10.1007/s00280-018-3757-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30542769/&quot;>https://pubmed.ncbi.nlm.nih.gov/30542769</a></p></li><li><p>Freise, KJ, &amp; Martín-Jiménez, T (2006). Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. <i>Journal of veterinary pharmacology and therapeutics</i> 29(2) 147–152. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.2006.00726.x&quot;>10.1111/j.1365-2885.2006.00726.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16515669/&quot;>https://pubmed.ncbi.nlm.nih.gov/16515669</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01BC05;
